LGI3

Summary

LGI3 (leucine rich repeat LGI family member 3, HGNC:18711) is a protein-coding gene on chromosome 8p21.3, encoding Leucine-rich repeat LGI family member 3 (Q8N145). May participate in the regulation of neuronal exocytosis.

Predicted to be involved in regulation of exocytosis. Located in extracellular space.

Source: NCBI Gene 203190 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 127 total — 10 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 23
• MANE Select transcript: NM_139278

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18711
Approved symbol	LGI3
Name	leucine rich repeat LGI family member 3
Location	8p21.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000168481
Ensembl biotype	protein_coding
OMIM	608302
Entrez	203190

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000306317, ENST00000424267, ENST00000517694, ENST00000518365, ENST00000520124, ENST00000950199, ENST00000950200, ENST00000950201, ENST00000950202

RefSeq mRNA: 1 — MANE Select: NM_139278 NM_139278

CCDS: CCDS6025

Canonical transcript exons

ENST00000306317 — 8 exons

Exon	Start	End
ENSE00001159088	22155392	22155463
ENSE00001287155	22156337	22156806
ENSE00003458770	22153968	22154039
ENSE00003482756	22154560	22154631
ENSE00003489369	22151489	22151653
ENSE00003493450	22151831	22152000
ENSE00003566850	22146830	22148977
ENSE00003682580	22154142	22154213

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 96.60.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.7318 / max 216.4268, expressed in 156 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
92209	2.2860	147
92208	0.1712	69
92207	0.1174	63
205097	0.0944	57
92210	0.0628	41

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	96.60	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.22	gold quality
prefrontal cortex	UBERON:0000451	96.10	gold quality
right frontal lobe	UBERON:0002810	95.82	gold quality
spinal cord	UBERON:0002240	95.51	gold quality
putamen	UBERON:0001874	94.83	gold quality
frontal cortex	UBERON:0001870	94.12	gold quality
caudate nucleus	UBERON:0001873	93.73	gold quality
substantia nigra	UBERON:0002038	93.09	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.75	gold quality
hypothalamus	UBERON:0001898	92.62	gold quality
midbrain	UBERON:0001891	92.59	gold quality
anterior cingulate cortex	UBERON:0009835	92.59	gold quality
inferior vagus X ganglion	UBERON:0005363	92.23	gold quality
neocortex	UBERON:0001950	92.00	gold quality
corpus callosum	UBERON:0002336	91.73	gold quality
nucleus accumbens	UBERON:0001882	91.60	gold quality
cerebral cortex	UBERON:0000956	90.72	gold quality
primary visual cortex	UBERON:0002436	90.42	gold quality
amygdala	UBERON:0001876	90.33	gold quality
occipital lobe	UBERON:0002021	90.26	gold quality
Ammon’s horn	UBERON:0001954	90.17	gold quality
postcentral gyrus	UBERON:0002581	89.93	gold quality
parietal lobe	UBERON:0001872	89.80	gold quality
lateral globus pallidus	UBERON:0002476	89.66	gold quality
superior frontal gyrus	UBERON:0002661	89.49	gold quality
lateral nuclear group of thalamus	UBERON:0002736	89.07	gold quality
forebrain	UBERON:0001890	88.88	gold quality
brain	UBERON:0000955	88.42	gold quality
subthalamic nucleus	UBERON:0001906	88.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	20.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

46 targeting LGI3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-6797-3P	99.17	66.94	668
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-6076	98.61	65.69	637
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-3180	98.46	64.68	348
HSA-MIR-3180-3P	98.46	64.68	348
HSA-MIR-6816-5P	98.46	64.35	364
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488

Literature-anchored findings (GeneRIF, showing 6)

• LGI3 was mostly expressed in the granular layer of the epidermis of human skin. (PMID:23815230)
• Leucine-rich glioma inactivated 3 is a cytokine in human skin that promotes melanin production. (PMID:24903553)
• The expression of LGI3 was significantly associated with the prognosis of brain, colorectal and lung cancer. (PMID:29257304)
• Taken together, these results suggest that LGI3 promotes keratinocyte differentiation. (PMID:30091803)
• LGI3 is secreted and binds to ADAM22 via TRIF-dependent NF-kappaB pathway in response to LPS in human keratinocytes. (PMID:31627033)
• LGI3 promotes human keratinocyte migration in high-glucose environments by increasing the expression of beta-catenin. (PMID:35751164)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	lgi3	ENSDARG00000041358
mus_musculus	Lgi3	ENSMUSG00000033595
rattus_norvegicus	Lgi3	ENSRNOG00000011323
drosophila_melanogaster	Con	FBGN0005775
drosophila_melanogaster	kek3	FBGN0028370
caenorhabditis_elegans	lron-9	WBGENE00011971
caenorhabditis_elegans		WBGENE00020649

Paralogs (22): CHADL (ENSG00000100399), LGI1 (ENSG00000108231), LGR6 (ENSG00000133067), CHAD (ENSG00000136457), LRIG3 (ENSG00000139263), LGR5 (ENSG00000139292), LRIG1 (ENSG00000144749), LRRTM2 (ENSG00000146006), LRIT1 (ENSG00000148602), LGI2 (ENSG00000153012), LGI4 (ENSG00000153902), LRRC52 (ENSG00000162763), ELFN2 (ENSG00000166897), LRG1 (ENSG00000171236), CPN2 (ENSG00000178772), LRIT3 (ENSG00000183423), LRRC26 (ENSG00000184709), LRIG2 (ENSG00000198799), LGR4 (ENSG00000205213), ELFN1 (ENSG00000225968), LRRC24 (ENSG00000254402), TRIL (ENSG00000255690)

Protein

Protein identifiers

Leucine-rich repeat LGI family member 3 — Q8N145 (reviewed: Q8N145)

Alternative names: LGI1-like protein 4, Leucine-rich glioma-inactivated protein 3

All UniProt accessions (3): E5RIV5, Q8N145, H0YAP4

UniProt curated annotations — full annotation on UniProt →

Function. May participate in the regulation of neuronal exocytosis.

Subunit / interactions. Interacts with STX1A.

Subcellular location. Secreted. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle. Synapse. Synaptosome. Cell projection. Axon.

Tissue specificity. Widely expressed, with highest levels in brain and lung.

Disease relevance. Intellectual developmental disorder with muscle tone abnormalities and distal skeletal defects (IDDMDS) [MIM:620007] An autosomal recessive disorder characterized by global developmental delay, intellectual disability, distal deformities with diminished reflexes, visible facial myokymia, and distinctive electromyographic features suggestive of motor nerve instability. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N145-1	1	yes
Q8N145-2	2

RefSeq proteins (1): NP_644807* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR005492	EPTP	Repeat
IPR009039	EAR	Repeat
IPR011041	Quinoprot_gluc/sorb_DH_b-prop	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR051295	LGI_related	Family

Pfam: PF03736, PF13855

UniProt features (22 total): repeat 10, sequence variant 4, glycosylation site 2, domain 2, signal peptide 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N145-F1	92.09	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 189, 311

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5682910	LGI-ADAM interactions
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 125 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_VESICLE_MEDIATED_TRANSPORT, CAGCTG_AP4_Q5, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS, YGACNNYACAR_UNKNOWN, chr8p21, GOBP_SECRETION, TGANTCA_AP1_C, NRF2_Q4, GOCC_NEURON_PROJECTION, GOBP_REGULATION_OF_TRANSPORT, IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM

GO Biological Process (2): exocytosis (GO:0006887), regulation of exocytosis (GO:0017157)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (9): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), synaptic vesicle (GO:0008021), juxtaparanode region of axon (GO:0044224), axon (GO:0030424), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995), neuron projection (GO:0043005), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
exocytosis	1
regulation of vesicle-mediated transport	1
regulation of secretion by cell	1
binding	1
exocytic vesicle	1
presynapse	1
main axon	1
neuron projection	1
cytoplasm	1
intracellular vesicle	1
plasma membrane bounded cell projection	1
cell junction	1

Protein interactions and networks

STRING

1470 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LGI3	ADAM23	O75077	850
LGI3	ADAM22	Q9P0K1	842
LGI3	ADAM28	Q9UKQ2	688
LGI3	MTUS1	Q9ULD2	622
LGI3	ADAM11	O75078	454
LGI3	LGI1	O95970	419
LGI3	PHYHIP	Q92561	400
LGI3	DLG2	Q15700	384
LGI3	MPP3	Q13368	372
LGI3	CHMP7	Q8WUX9	366
LGI3	FGF18	O76093	347
LGI3	LGI4	Q8N135	331
LGI3	MITF	O75030	312
LGI3	LRRC7	Q96NW7	294
LGI3	RNF186	Q9NXI6	290

IntAct

2 interactions, top by confidence:

A	B	Type	Score
RSPH1	LGI3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (2): LGI3 (Two-hybrid), LGI3 (Affinity Capture-MS)

ESM2 similar proteins: A6H793, D3ZPX4, F1MMS9, J3S6Y1, O75325, O75578, P08514, P08648, P11688, P17852, P26006, P35739, P38570, P51805, P59034, P59035, P70206, P70208, Q13683, Q1EGL0, Q1EGL1, Q27977, Q2EEY0, Q3UFB7, Q3UFQ8, Q4R4H3, Q5I2M3, Q5I2M4, Q5I2M5, Q5I2M7, Q5I2M8, Q5STE3, Q5XHY1, Q62179, Q62470, Q63258, Q6MZW2, Q8K1S1, Q8K406, Q8K4Z0

Diamond homologs: O95970, P24014, Q1EGL0, Q1EGL1, Q1EGL2, Q4R4H3, Q5E9T6, Q5R945, Q6EMK4, Q8K1S1, Q8K406, Q8K4Y5, Q8K4Z0, Q8N0V4, Q8N135, Q8N145, Q9CZT5, Q9JIA1, Q9WVC1, P70193, O88279, Q80TR4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	1
Uncertain significance	97
Likely benign	7
Benign	5

Top pathogenic / likely-pathogenic (11)

Variant ID	HGVS	Classification
1699925	NC_000008.11:g.22146137_22152989del	Pathogenic
1699926	NM_139278.4(LGI3):c.494+1G>C	Pathogenic
1699927	NM_139278.4(LGI3):c.335C>A (p.Ser112Ter)	Pathogenic
1699928	NM_139278.4(LGI3):c.991G>A (p.Asp331Asn)	Pathogenic
1699929	NM_139278.4(LGI3):c.1117del (p.Trp373fs)	Pathogenic
1699930	NM_139278.4(LGI3):c.422T>A (p.Leu141His)	Pathogenic
1699931	NM_139278.4(LGI3):c.830-1G>A	Pathogenic
1699932	NM_139278.4(LGI3):c.102dup (p.Lys35fs)	Pathogenic
1699933	NM_139278.4(LGI3):c.937del (p.Thr313fs)	Pathogenic
2430614	NM_139278.4(LGI3):c.271C>T (p.Gln91Ter)	Pathogenic
3367082	NM_139278.4(LGI3):c.625C>T (p.Gln209Ter)	Likely pathogenic

SpliceAI

1192 predictions. Top by Δscore:

Variant	Effect	Δscore
8:22148973:GGGGG:G	acceptor_gain	1.0000
8:22148974:GGGG:G	acceptor_gain	1.0000
8:22148975:GGG:G	acceptor_gain	1.0000
8:22148977:GC:G	acceptor_loss	1.0000
8:22148978:C:CC	acceptor_gain	1.0000
8:22148984:C:CT	acceptor_gain	1.0000
8:22148984:C:T	acceptor_gain	1.0000
8:22148985:A:T	acceptor_gain	1.0000
8:22151484:GGTAC:G	donor_loss	1.0000
8:22151485:GTAC:G	donor_loss	1.0000
8:22151486:TACCT:T	donor_loss	1.0000
8:22151487:A:C	donor_loss	1.0000
8:22151488:C:CG	donor_loss	1.0000
8:22151654:C:CC	acceptor_gain	1.0000
8:22151828:TA:T	donor_loss	1.0000
8:22151996:GGTCC:G	acceptor_gain	1.0000
8:22151997:GTCC:G	acceptor_gain	1.0000
8:22151998:TCC:T	acceptor_gain	1.0000
8:22151999:CC:C	acceptor_gain	1.0000
8:22151999:CCC:C	acceptor_gain	1.0000
8:22152000:CC:C	acceptor_gain	1.0000
8:22152001:C:CC	acceptor_gain	1.0000
8:22152001:C:T	acceptor_gain	1.0000
8:22152001:CTG:C	acceptor_loss	1.0000
8:22152002:T:C	acceptor_loss	1.0000
8:22152004:C:CT	acceptor_gain	1.0000
8:22152007:C:CT	acceptor_gain	1.0000
8:22152008:A:AC	acceptor_gain	1.0000
8:22152008:A:C	acceptor_gain	1.0000
8:22152008:A:T	acceptor_gain	1.0000

AlphaMissense

3555 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:22151955:C:A	W180C	1.000
8:22151955:C:G	W180C	1.000
8:22154024:A:C	N146K	1.000
8:22154024:A:T	N146K	1.000
8:22154142:A:G	L141P	1.000
8:22154151:A:C	L138W	1.000
8:22154198:A:C	N122K	1.000
8:22154198:A:T	N122K	1.000
8:22154210:G:C	F118L	1.000
8:22154210:G:T	F118L	1.000
8:22154211:A:C	F118C	1.000
8:22154212:A:G	F118L	1.000
8:22154560:A:G	L117P	1.000
8:22154587:A:C	F108C	1.000
8:22154587:A:G	F108S	1.000
8:22155419:A:C	F84C	1.000
8:22156337:A:G	L69P	1.000
8:22151532:C:A	W262C	0.999
8:22151532:C:G	W262C	0.999
8:22151650:A:G	F223S	0.999
8:22151904:G:C	C197W	0.999
8:22151905:C:G	C197S	0.999
8:22151906:A:T	C197S	0.999
8:22151943:C:A	W184C	0.999
8:22151943:C:G	W184C	0.999
8:22151974:C:G	C174S	0.999
8:22151975:A:T	C174S	0.999
8:22151985:G:C	N170K	0.999
8:22151985:G:T	N170K	0.999
8:22154025:T:A	N146I	0.999

dbSNP variants (sampled 300 via entrez): RS1000063065 (8:22148077 C>T), RS1000634636 (8:22146573 C>G,T), RS1000909861 (8:22157383 A>C), RS1001574006 (8:22147354 C>G), RS1001643674 (8:22158410 A>C), RS1001942818 (8:22158074 G>A), RS1001983020 (8:22147174 G>A), RS1002015677 (8:22146917 C>G), RS1002351984 (8:22157806 A>G), RS1002487919 (8:22154714 T>A,C), RS1002725348 (8:22155739 A>G), RS1002837048 (8:22153325 T>C), RS1003021824 (8:22147786 C>T), RS1003549888 (8:22153530 G>A,T), RS1003907648 (8:22153097 A>T)

Disease associations

OMIM: gene MIM:608302 | disease phenotypes: MIM:620007

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal recessive
intellectual developmental disorder with muscle tone abnormalities and distal skeletal defects	Limited	Autosomal recessive

Mondo (2): intellectual developmental disorder with muscle tone abnormalities and distal skeletal defects (MONDO:0859277), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

23 total (23 of 23 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000160	Narrow mouth
HP:0000253	Progressive microcephaly
HP:0000317	Facial myokymia
HP:0000739	Anxiety
HP:0000768	Pectus carinatum
HP:0000964	Eczematoid dermatitis
HP:0001249	Intellectual disability
HP:0001251	Ataxia
HP:0001263	Global developmental delay
HP:0001265	Hyporeflexia
HP:0001308	Tongue fasciculations
HP:0001385	Hip dysplasia
HP:0001508	Failure to thrive
HP:0002375	Hypokinesia
HP:0002411	Myokymia
HP:0002808	Kyphosis
HP:0003593	Infantile onset
HP:0004322	Short stature
HP:0007018	Attention deficit hyperactivity disorder
HP:0008936	Axial hypotonia
HP:0011463	Childhood onset
HP:0012389	Appendicular hypotonia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001905_1	Hypertriglyceridemia	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sotorasib	affects cotreatment, decreases expression	1
butylbenzyl phthalate	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Dactinomycin	affects cotreatment, increases expression	1
Endosulfan	increases expression	1
Methotrexate	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice